ES2157309T3 - Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas. - Google Patents

Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas.

Info

Publication number
ES2157309T3
ES2157309T3 ES95810545T ES95810545T ES2157309T3 ES 2157309 T3 ES2157309 T3 ES 2157309T3 ES 95810545 T ES95810545 T ES 95810545T ES 95810545 T ES95810545 T ES 95810545T ES 2157309 T3 ES2157309 T3 ES 2157309T3
Authority
ES
Spain
Prior art keywords
radiomarcated
somatostatine
compositions
chelating groups
analogs containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95810545T
Other languages
English (en)
Inventor
Rainer Albert
Christian Bruns
Peter Smith-Jones
Barbara Stolz
Gisbert Weckbecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2157309T3 publication Critical patent/ES2157309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) EN LA QUE M ES UN EQUIVALENTE DE CATION Y A ES PHE O TYR, EN LA FORMA LIBRE O EN FORMA DE SAL, LOS COMPUESTOS SON UTILES COMO PRODUCTOS RADIOFARMACOLOGICOS CUANDO SE COMPLEJAN CON UN RADIONUCLEOTIDO EMISOR DE {AL} O DE {BE} O UN NUCLIDO CON CASCADAS DE E{SP,-} DE AUGER.
ES95810545T 1994-09-06 1995-09-04 Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas. Expired - Lifetime ES2157309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417873A GB9417873D0 (en) 1994-09-06 1994-09-06 Organic compounds

Publications (1)

Publication Number Publication Date
ES2157309T3 true ES2157309T3 (es) 2001-08-16

Family

ID=10760870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95810545T Expired - Lifetime ES2157309T3 (es) 1994-09-06 1995-09-04 Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas.

Country Status (31)

Country Link
US (2) US6183721B1 (es)
EP (1) EP0714911B1 (es)
JP (1) JP3054346B2 (es)
KR (1) KR100364111B1 (es)
CN (1) CN1185252C (es)
AT (1) ATE199561T1 (es)
AU (1) AU703057B2 (es)
BR (1) BR9503936A (es)
CA (1) CA2157530C (es)
CO (1) CO4410344A1 (es)
CZ (1) CZ287012B6 (es)
DE (1) DE69520256T2 (es)
DK (1) DK0714911T3 (es)
ES (1) ES2157309T3 (es)
FI (1) FI117424B (es)
GB (1) GB9417873D0 (es)
GR (1) GR3035997T3 (es)
HU (1) HU218284B (es)
IL (1) IL115154A (es)
NO (1) NO316569B1 (es)
NZ (1) NZ272919A (es)
PE (1) PE41496A1 (es)
PL (1) PL182434B1 (es)
PT (1) PT714911E (es)
RU (1) RU2156774C2 (es)
SG (1) SG50356A1 (es)
SI (1) SI0714911T1 (es)
SK (1) SK283774B6 (es)
TR (1) TR199501094A2 (es)
TW (1) TW387898B (es)
ZA (1) ZA957475B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
CN1551767A (zh) 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
BR0207315A (pt) * 2001-02-26 2004-02-10 Bristol Myers Squibb Pharma Co Análogos de ácido ascórbico para metalorradiofármacos
AU2002305845B2 (en) * 2001-06-08 2006-03-30 Ipsen Pharma S.A.S. Somatostatin-dopamine chimeric analogs
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
US7211250B2 (en) 2002-07-18 2007-05-01 Helix Biopharma Corporation Method and composition for inhibiting cancer cell growth
JP2006522100A (ja) * 2003-03-10 2006-09-28 バイオジェン アイデック インク 標的化ペプチドに対するチオール媒介性薬物結合
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20100029911A1 (en) * 2004-11-24 2010-02-04 Aplagen Gmbh Method For Solid-Phase Peptide Synthesis And Purification
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20140170068A1 (en) 2011-03-11 2014-06-19 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
EP2922578B1 (en) 2012-11-21 2018-12-12 Serene, Llc Tin-117m comprising somatostatin receptor binding compounds
CN103275189B (zh) * 2013-06-06 2014-08-06 深圳翰宇药业股份有限公司 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用
AU2014336638C1 (en) * 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3383920B1 (en) 2015-11-30 2024-01-10 The Regents of the University of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US11235076B2 (en) 2016-08-29 2022-02-01 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
EP3538551A4 (en) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CA3050094C (en) 2017-01-12 2024-01-02 Radiomedix Inc. Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
TW202015744A (zh) * 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202547563A (zh) * 2018-06-21 2025-12-16 德商愛利穆治療有限公司 用於放射性醫藥之含有體抑素類似物之組成物
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US20200030466A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
JP2023534765A (ja) 2020-08-07 2023-08-10 フォーティス セラピューティクス，インク． 免疫複合体を標的とするｃｄ４６およびその使用方法
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
JPWO2025058000A1 (es) 2023-09-13 2025-03-20

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725577A (en) * 1985-04-25 1988-02-16 Administrators Of The Tulane Educational Fund Biologically active lysine containing octapeptides
US5006643A (en) 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
DE3728600A1 (de) 1987-08-27 1989-03-09 Hoechst Ag Verfahren zur markierung von substanzen mit technetium oder rhenium
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
WO1991004755A1 (en) 1989-09-29 1991-04-18 Neorx Corporation Methods for reducing non-target retention of immunoconjugates and metabolites thereof
JPH07505621A (ja) * 1992-03-25 1995-06-22 マリンクロッド・インコーポレイテッド 外科手術中における腫瘍組織の検出および探知法
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
NO940080L (no) * 1993-01-12 1994-07-13 Sandoz Ag Polypeptider , fremgangsmåte for deres fremstilling og farmasöytiske preparater derav
CA2179990A1 (en) * 1994-01-12 1995-07-20 Gary Robert Bower Biological targeting agents
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
TW387898B (en) 2000-04-21
NO953457L (no) 1996-03-07
DE69520256D1 (de) 2001-04-12
ATE199561T1 (de) 2001-03-15
PE41496A1 (es) 1996-10-14
PL182434B1 (pl) 2002-01-31
FI117424B (fi) 2006-10-13
SK108895A3 (en) 1996-06-05
JP3054346B2 (ja) 2000-06-19
FI954147A0 (fi) 1995-09-04
DK0714911T3 (da) 2001-07-09
DE69520256T2 (de) 2001-08-09
HUT72895A (en) 1996-06-28
NO316569B1 (no) 2004-02-23
AU3041495A (en) 1996-03-21
GB9417873D0 (en) 1994-10-26
KR960010683A (ko) 1996-04-20
US6277356B1 (en) 2001-08-21
CZ287012B6 (en) 2000-08-16
FI954147L (fi) 1996-03-07
ZA957475B (en) 1997-03-06
EP0714911A2 (en) 1996-06-05
NO953457D0 (no) 1995-09-04
HU218284B (en) 2000-07-28
GR3035997T3 (en) 2001-09-28
CN1185252C (zh) 2005-01-19
CN1127259A (zh) 1996-07-24
PT714911E (pt) 2001-08-30
SI0714911T1 (en) 2001-08-31
TR199501094A2 (tr) 1996-06-21
SK283774B6 (sk) 2004-01-08
RU2156774C2 (ru) 2000-09-27
HU9502577D0 (en) 1995-11-28
SG50356A1 (en) 2000-11-21
CZ226395A3 (en) 1996-03-13
EP0714911B1 (en) 2001-03-07
US6183721B1 (en) 2001-02-06
KR100364111B1 (ko) 2003-02-05
NZ272919A (en) 1996-12-20
CA2157530C (en) 2007-04-03
AU703057B2 (en) 1999-03-11
PL310274A1 (en) 1996-03-18
EP0714911A3 (en) 1996-08-21
CO4410344A1 (es) 1997-01-09
CA2157530A1 (en) 1996-03-07
BR9503936A (pt) 1996-09-24
IL115154A (en) 2000-08-13
IL115154A0 (en) 1995-12-31
JPH0881498A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
ES2118095T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
DE69814514D1 (de) Zusammensetzungen auf Basis von Wasser zur Abdichtung von unterirdischen Lagerstätten
MX9101445A (es) Composiciones de organosilicio que contienen elastomeros hidrocarburo
MX156804A (es) Mejoras a composicion blanqueadora estabilizada que contiene enzimas
ES2100907T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y proced imiento para su preparacion.
ES2099436T3 (es) Compuestos biologicamente activos de tipo fosfotriesteres.
ES8706164A1 (es) Un procedimiento para la preparacion de glicosidos de homo- nojirimicina
ES2149378T3 (es) Procedimiento para la sulfonilacion, sulfenilacion y fosforilacion de depsipeptidos ciclicos.
MX9700249A (es) Compuestos ariltios como agentes antibacteriales yantivirales.
CO4410344A1 (es) Peptidos de somatostina como radiofarmacos, proceso para su produccion y preparaciones farmaceuticas que los contienen .
GR79462B (es)
DK208186A (da) P-sulfofenylalkylkarbonater samt detergentblandinger og detergentadditiver indeholdende saadanne forbindelser
MX9709398A (es) N-aril-1,2,4-triazolin-5-onas.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
FR2572399B1 (fr) Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant
ES2161446T3 (es) Taxoides, su preparacion y las composiciones farmaceuticas que les contienen.
NO960633L (no) Mineralfiberblandinger
FI900933A0 (fi) Biocidala kompositioner och behandlingar.
FR2536756B1 (fr) Compositions asphaltiques renforcees par des fibres
ES2093286T3 (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2179484T3 (es) Perfumes que comprenden 3-alquilcicloalcanoles.
ES2057894T3 (es) Activadores para percompuestos inorganicos.
FI822099A0 (fi) Maettade aminocyklitderivat, deras framstaellning och dessa innehaollande laekemedel
ES2131036B1 (es) Material de grabacion fotografica en color.
MX9306178A (es) Bencimidazoles medicamentos que contienen estos compuestos yprocedimientos para su preparacion.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 714911

Country of ref document: ES